Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Anemia
11%
Antivirus Agent
24%
Boceprevir
32%
Chronic Hepatitis C
34%
Clinical Trial
12%
Complication
7%
Daclatasvir
9%
Dasabuvir
10%
Decompensated Liver Cirrhosis
9%
Diseases
7%
Drug
14%
Fatigue
7%
Fibrosis
9%
Glecaprevir
6%
Glecaprevir Plus Pibrentasvir
11%
Headache
5%
Hepatic Encephalopathy
13%
Hepatitis B
7%
Hepatitis B Virus
5%
Hepatitis C
33%
Hepatitis C Virus
46%
Hepatitis C Virus Genotype 1
26%
Infection
43%
Interferon
24%
Lamivudine
6%
Ledipasvir Plus Sofosbuvir
6%
Liver Cirrhosis
43%
Liver Disease
14%
Nonalcoholic Fatty Liver
8%
Nonstructural Protein 5A Inhibitor
7%
Ombitasvir
14%
Paritaprevir
11%
Peginterferon
35%
Peginterferon Alpha
9%
Pibrentasvir
6%
Placebo
18%
Portal Hypertension
5%
Proteinase Inhibitor
11%
Recurrent Disease
6%
Relapse
8%
Ribavirin
95%
Rifaximin
5%
Ritonavir
15%
RNA
5%
Simeprevir
14%
Sofosbuvir
13%
Telaprevir
8%
Virus
7%
Virus RNA
12%
Medicine and Dentistry
Adverse Event
10%
Antivirus Agent
8%
Boceprevir
7%
Chronic Hepatitis C
12%
Chronic Liver Disease
8%
Combination Therapy
37%
Complication
9%
Dasabuvir
5%
Decompensated Liver Cirrhosis
5%
Development
7%
Diagnosis
6%
Diseases
9%
Fibrosis
12%
Genotype
12%
Health Care Cost
7%
Hepatic Encephalopathy
10%
Hepatitis B
8%
Hepatitis B Virus
5%
Hepatitis C
16%
Hepatitis C Virus
22%
Hepatitis C Virus Genotype 1
5%
Hepatocellular Carcinoma
10%
Infection
15%
Inpatient
21%
Interferon
12%
Liver
9%
Liver Biopsy
7%
Liver Cirrhosis
19%
Liver Disease
11%
Liver Transplantation
24%
Nonalcoholic Fatty Liver
18%
Odds Ratio
5%
Ombitasvir
5%
Patient
100%
Peginterferon
11%
Platelet
11%
Portal Hypertension
7%
Prevalence
5%
Recurrent Disease
6%
Relapse
5%
Ribavirin
27%
Ritonavir
6%
Therapeutic Procedure
58%
Thrombocytopenia
14%
Tioguanine
5%
Transplantation
6%
Nursing and Health Professions
Adverse Event
5%
Boceprevir
5%
Chronic Hepatitis C
10%
Combination Therapy
14%
Hepatitis C
12%
Infection
11%
Inpatient
6%
Liver Cirrhosis
12%
Patient
50%
Peginterferon
5%
Ribavirin
22%
Ritonavir
5%
Sustained Virologic Response
17%
Treatment Duration
6%